Abstract
Epithelial–mesenchymal plasticity (EMP) enables cells to interconvert between several states across the epithelial–mesenchymal landscape, thereby acquiring hybrid epithelial/mesenchymal phenotypic features. This plasticity is crucial for embryonic development and wound healing, but also underlies the acquisition of several malignant traits during cancer progression. Recent research using systems biology and single-cell profiling methods has provided novel insights into the main forces that shape EMP, which include the microenvironment, lineage specification and cell identity, and the genome. Additionally, key roles have emerged for hysteresis (cell memory) and cellular noise, which can drive stochastic transitions between cell states. Here, we review these forces and the distinct but interwoven layers of regulatory control that stabilize EMP states or facilitate epithelial–mesenchymal transitions (EMTs) and discuss the therapeutic potential of manipulating the EMP landscape.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Waddington, C. H. The Strategy of the Genes (Routledge, 2014).
Kalluri, R. & Weinberg, R. A. The basics of epithelial–mesenchymal transition. J. Clin. Invest. 119, 1420–1428 (2009).
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016).
Yang, J. et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341–352 (2020). This consensus statement clarifies the nomenclature used in the EMT field and provides guidelines for EMT research.
Hay, E. D. in Epithelial–Mesenchymal Interactions; 18th Hahnemann Symposium (eds Fleischmajer, R. & Billingham, R. E.) 31–35 (Williams & Wilkins, 1968).
Hay, E. D. An overview of epithelio-mesenchymal transformation. Acta Anat. 154, 8–20 (1995).
Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442–454 (2002).
Cook, D. P. & Vanderhyden, B. C. Context specificity of the EMT transcriptional response. Nat. Commun. 11, 2142 (2020). This comparative analysis uses time-course, single-cell RNA sequencing of EMT responses that highlights their diversity across systems.
Dong, J. et al. Single-cell RNA-seq analysis unveils a prevalent epithelial/mesenchymal hybrid state during mouse organogenesis. Genome Biol. 19, 31 (2018).
Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624.e24 (2017).
Zhao, J. et al. Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma. Cancer Lett. 477, 131–143 (2020).
Ji, A. L. et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell 182, 1661–1662 (2020).
McFaline-Figueroa, J. L. et al. A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. Nat. Genet. 51, 1389–1398 (2019).
Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2102050118 (2021).
Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150–1162.e9 (2021).
Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018). Using a large panel of cell surface markers, this study is the first to provide strong, in vivo evidence for intermediate EMT states with distinct functional characteristics.
Karacosta, L. G. et al. Mapping lung cancer epithelial–mesenchymal transition states and trajectories with single-cell resolution. Nat. Commun. 10, 5587 (2019).
Taverna, J. A. et al. Single-cell proteomic profiling identifies combined AXL and JAK1 inhibition as a novel therapeutic strategy for lung cancer. Cancer Res. 80, 1551–1563 (2020).
Pastushenko, I. & Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29, 212–226 (2019).
Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448–455 (2021).
Kroger, C. et al. Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proc. Natl Acad. Sci. USA 116, 7353–7362 (2019). This study finds that a hybrid EMT state results in high tumorigenic potential, whereas fully epithelial or mesenchymal cells, or a combination thereof, show poor tumorigenic potential.
Potts, J. D. & Runyan, R. B. Epithelial–mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor β. Dev. Biol. 134, 392–401 (1989).
Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127, 2021–2036 (1994).
Stoker, M. & Perryman, M. An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 77, 209–223 (1985).
Valles, A. M. et al. Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc. Natl Acad. Sci. USA 87, 1124–1128 (1990).
Kim, K., Lu, Z. & Hay, E. D. Direct evidence for a role of β-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 26, 463–476 (2002).
Timmerman, L. A. et al. Notch promotes epithelial–mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 18, 99–115 (2004).
Lester, R. D., Jo, M., Montel, V., Takimoto, S. & Gonias, S. L. uPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 178, 425–436 (2007).
Yang, M. H. et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat. Cell Biol. 10, 295–305 (2008).
Loayza-Puch, F. et al. TGFβ1-induced leucine limitation uncovered by differential ribosome codon reading. EMBO Rep. 18, 549–557 (2017).
Recouvreux, M. V. et al. Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. J. Exp. Med. https://doi.org/10.1084/jem.20200388 (2020).
Nakasuka, F. et al. TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancers. Commun. Biol. 4, 782 (2021).
Heise, R. L., Stober, V., Cheluvaraju, C., Hollingsworth, J. W. & Garantziotis, S. Mechanical stretch induces epithelial–mesenchymal transition in alveolar epithelia via hyaluronan activation of innate immunity. J. Biol. Chem. 286, 17435–17444 (2011).
Przybyla, L., Muncie, J. M. & Weaver, V. M. Mechanical control of epithelial-to-mesenchymal transitions in development and cancer. Annu. Rev. Cell Dev. Biol. 32, 527–554 (2016).
Zhao, X., Hu, J., Li, Y. & Guo, M. Volumetric compression develops noise-driven single-cell heterogeneity. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2110550118 (2021).
Fattet, L. et al. Matrix rigidity controls epithelial–mesenchymal plasticity and tumor metastasis via a mechanoresponsive EPHA2/LYN complex. Dev. Cell 54, 302–316.e7 (2020).
Deng, Y., Chakraborty, P., Jolly, M. K. & Levine, H. A theoretical approach to coupling the epithelial–mesenchymal transition (EMT) to extracellular matrix (ECM) stiffness via LOXL2. Cancers https://doi.org/10.3390/cancers13071609 (2021).
Gao, Y. et al. Metastasis organotropism: redefining the congenial soil. Dev. Cell 49, 375–391 (2019).
Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590 (2011).
Kan, T. et al. Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene 39, 4227–4240 (2020).
Szczerba, B. M. et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566, 553 (2019).
Liu, Q., Liao, Q. & Zhao, Y. Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance. Med. Hypotheses 87, 34–39 (2016).
Sprouse, M. L. et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/nodal signaling. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20081916 (2019).
Hurtado, P., Martinez-Pena, I. & Pineiro, R. Dangerous liaisons: circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs). Cancers https://doi.org/10.3390/cancers12102861 (2020).
Xiong, G. et al. Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell–platelet interaction. Proc. Natl Acad. Sci. USA 117, 3748–3758 (2020).
Hou, J. M. et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30, 525–532 (2012).
Paoli, P., Giannoni, E. & Chiarugi, P. Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acta 1833, 3481–3498 (2013).
Giuliano, M. et al. Perspective on circulating tumor cell clusters: why it takes a village to metastasize. Cancer Res. 78, 845–852 (2018).
Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110–1122 (2014).
Cheung, K. J. et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl Acad. Sci. USA 113, E854–E863 (2016).
Sarioglu, A. F. et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat. Methods 12, 685–691 (2015).
Beard, J. Embryological aspects and etiology of carcinoma. Lancet 159, 1758–1761 (1902).
Virchow, R. Vorlesungen über cellularpathologie in ihrer Begründung auf physiologischer und pathologischer Gewebelehre (Verlag August Hirschwald, 1858).
Markert, C. L. Neoplasia: a disease of cell differentiation. Cancer Res. 28, 1908–1914 (1968).
Micalizzi, D. S., Farabaugh, S. M. & Ford, H. L. Epithelial–mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary Gland. Biol. 15, 117–134 (2010).
Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342, 1234850 (2013).
Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial–mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
Pritchard, C. et al. Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res. 69, 1739–1747 (2009).
Pomerantz, M. M. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat. Genet. 52, 790–799 (2020).
Schaeffer, E. M. et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 27, 7180–7191 (2008).
Roe, J. S. et al. Enhancer reprogramming promotes pancreatic cancer metastasis. Cell 170, 875–888.e20 (2017).
Gupta, P. B. et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047–1054 (2005).
Holczbauer, A. et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 145, 221–231 (2013).
Latil, M. et al. Cell-type-specific chromatin states differentially prime squamous cell carcinoma tumor-initiating cells for epithelial to mesenchymal transition. Cell Stem Cell 20, 191–204.e5 (2017). This study illustrates how the cancer cell of origin controls EMT propensity during further tumour development through transcriptional and epigenetic priming.
Chou, J., Provot, S. & Werb, Z. GATA3 in development and cancer differentiation: cells GATA have it! J. Cell. Physiol. 222, 42–49 (2010).
Bai, F. et al. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer. Theranostics 11, 8218 (2021).
Saotome, M., Poduval, D. B., Nair, R., Cooper, M. & Takaku, M. GATA3 truncation mutants alter EMT related gene expression via partial motif recognition in luminal breast cancer cells. Front. Genet. 13, 67 (2022).
Kouros-Mehr, H. et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141–152 (2008).
Yan, W., Cao, Q. J., Arenas, R. B., Bentley, B. & Shao, R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial–mesenchymal transition. J. Biol. Chem. 285, 14042–14051 (2010).
Li, Y. et al. Loss of GATA3 in bladder cancer promotes cell migration and invasion. Cancer Biol. Ther. 15, 428–435 (2014).
Chakrabarti, R. et al. Elf5 inhibits the epithelial–mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 14, 1212–1222 (2012).
Wu, B. et al. Epigenetic regulation of Elf5 is associated with epithelial–mesenchymal transition in urothelial cancer. PLoS ONE 10, e0117510 (2015).
Yao, B. et al. Elf5 inhibits TGF‐β‐driven epithelial–mesenchymal transition in prostate cancer by repressing SMAD3 activation. Prostate 75, 872–882 (2015).
Song, Y., Washington, M. K. & Crawford, H. C. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 70, 2115–2125 (2010).
Teng, M., Zhou, S., Cai, C., Lupien, M. & He, H. H. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell 12, 29–38 (2021).
Tiwari, N. et al. Klf4 is a transcriptional regulator of genes critical for EMT, including Jnk1 (Mapk8). PLoS ONE 8, e57329 (2013).
Agbo, K. C. et al. Loss of the Kruppel-like factor 4 tumor suppressor is associated with epithelial-mesenchymal transition in colorectal cancer. J. Cancer Metastasis Treat. https://doi.org/10.20517/2394-4722.2019.35 (2019).
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M. & Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67, 10123–10128 (2007).
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M. C. & Ten Dijke, P. TGF-β-induced endothelial–mesenchymal transition in fibrotic diseases. Int. J. Mol. Sci. https://doi.org/10.3390/ijms18102157 (2017).
Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282–2287 (2008).
Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952–961 (2007).
Tombor, L. S. et al. Single cell sequencing reveals endothelial plasticity with transient mesenchymal activation after myocardial infarction. Nat. Commun. 12, 681 (2021).
Lin, S. C. et al. Endothelial-to-osteoblast conversion generates osteoblastic metastasis of prostate cancer. Dev. Cell 41, 467–480 e463 (2017).
Medici, D. et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400–1406 (2010).
De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97–110 (2013).
Acloque, H., Adams, M. S., Fishwick, K., Bronner-Fraser, M. & Nieto, M. A. Epithelial–mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 119, 1438–1449 (2009).
Sanchez-Martin, M. et al. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum. Mol. Genet. 11, 3231–3236 (2002).
Zweier, C. et al. “Mowat-Wilson” syndrome with and without Hirschsprung disease is a distinct, recognizable multiple congenital anomalies–mental retardation syndrome caused by mutations in the zinc finger homeo Box 1B gene. Am. J. Med. Genet. 108, 177–181 (2002).
el Ghouzzi, V. et al. Mutations of the TWIST gene in the Saethre–Chotzen syndrome. Nat. Genet. 15, 42–46 (1997).
Howard, T. D. et al. Mutations in TWIST, a basic helix–loop–helix transcription factor, in Saethre–Chotzen syndrome. Nat. Genet. 15, 36–41 (1997).
Horiguchi, K. et al. Role of Ras signaling in the induction of snail by transforming growth factor-β. J. Biol. Chem. 284, 245–253 (2009).
Wang, Y. et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29, 4658–4670 (2010).
Zhang, X., Cheng, Q., Yin, H. & Yang, G. Regulation of autophagy and EMT by the interplay between p53 and RAS during cancer progression [Review]. Int. J. Oncol. 51, 18–24 (2017).
Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).
Bisogno, L. S., Friedersdorf, M. B. & Keene, J. D. Ras post-transcriptionally enhances a pre-malignantly primed EMT to promote invasion. iScience 4, 97–108 (2018).
Yoh, K. E. et al. Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells. Proc. Natl Acad. Sci. USA 113, E6107–E6116 (2016).
Grassian, A. R. et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial–mesenchymal transition (EMT). J. Biol. Chem. 287, 42180–42194 (2012).
Lu, J. et al. IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction. J. BUON 24, 2458–2464 (2019).
Jiang, Z. et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 10, 1563–1570 (2011).
Fedele, V. & Melisi, D. Permissive state of EMT: the role of immune cell compartment. Front. Oncol. 10, 587 (2020).
Quaresma, M. C. et al. Mutant CFTR drives TWIST1 mediated epithelial–mesenchymal transition. Cell Death Dis. 11, 920 (2020).
Gibson, R. L., Burns, J. L. & Ramsey, B. W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918–951 (2003).
Nichols, D., Chmiel, J. & Berger, M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin. Rev. Allergy Immunol. 34, 146–162 (2008).
Worlitzsch, D. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109, 317–325 (2002).
Harris, W. T. et al. Plasma TGF-β1 in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatr. Pulmonol. 46, 688–695 (2011).
Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399–416 (2018).
Dai, Y. et al. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling. Theranostics 9, 6063–6079 (2019).
Berenguer, J. & Celia-Terrassa, T. Cell memory of epithelial–mesenchymal plasticity in cancer. Curr. Opin. Cell Biol. 69, 103–110 (2021).
Ewing, J. A. V. I. I. On the production of transient electric currents in iron and steel conductors by twisting them when magnetised or by magnetising them when twisted. Proc. R. Soc. Lond. 33, 21–23 (1882).
Ferrell, J. E. Jr Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr. Opin. Cell Biol. 14, 140–148 (2002).
Gregory, P. A. et al. An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial–mesenchymal transition. Mol. Biol. Cell 22, 1686–1698 (2011).
Jain, P. et al. Epigenetic memory acquired during long-term EMT induction governs the recovery to the epithelial state. J. R. Soc. Interface 20, 20220627 (2023).
Stylianou, N. et al. A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome. Oncogene 38, 913–934 (2019).
Celia-Terrassa, T. et al. Hysteresis control of epithelial–mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat. Commun. 9, 5005 (2018). This study shows direct evidence for hysteresis, and its functional consequences, in EMT by uncoupling the miR-200–ZEB negative feedback loop.
Schmidt, J. M. et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 10, 131–139 (2015).
Sarrio, D., Franklin, C. K., Mackay, A., Reis-Filho, J. S. & Isacke, C. M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cell 30, 292–303 (2012).
Harner-Foreman, N. et al. A novel spontaneous model of epithelial–mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics. Sci. Rep. 7, 40633 (2017).
Ruscetti, M. et al. HDAC inhibition impedes epithelial–mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene 35, 3781–3795 (2016).
Mathis, R. A., Sokol, E. S. & Gupta, P. B. Cancer cells exhibit clonal diversity in phenotypic plasticity. Open. Biol. https://doi.org/10.1098/rsob.160283 (2017).
Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633–644 (2011).
Bhatia, S. et al. Interrogation of phenotypic plasticity between epithelial and mesenchymal states in breast cancer. J. Clin. Med. https://doi.org/10.3390/jcm8060893 (2019).
Mani, S. A. et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
Neelakantan, D. et al. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat. Commun. 8, 15773 (2017).
Lan, L. et al. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature https://doi.org/10.1038/s41586-022-04888-7 (2022).
Boareto, M. et al. Notch–Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. J. R. Soc. Interface https://doi.org/10.1098/rsif.2015.1106 (2016).
Jain, P., Bhatia, S., Thompson, E. W. & Jolly, M. K. Population dynamics of epithelial–mesenchymal heterogeneity in cancer cells. Biomolecules https://doi.org/10.3390/biom12030348 (2022).
Tripathi, S., Chakraborty, P., Levine, H. & Jolly, M. K. A mechanism for epithelial–mesenchymal heterogeneity in a population of cancer cells. PLoS Comput. Biol. 16, e1007619 (2020).
Elowitz, M. B., Levine, A. J., Siggia, E. D. & Swain, P. S. Stochastic gene expression in a single cell. Science 297, 1183–1186 (2002).
McAdams, H. H. & Arkin, A. Stochastic mechanisms in gene expression. Proc. Natl Acad. Sci. USA 94, 814–819 (1997).
Losick, R. & Desplan, C. Stochasticity and cell fate. Science 320, 65–68 (2008).
Jia, W. et al. Epigenetic feedback and stochastic partitioning during cell division can drive resistance to EMT. Oncotarget 11, 2611–2624 (2020).
Desai, R. V. et al. A DNA repair pathway can regulate transcriptional noise to promote cell fate transitions. Science https://doi.org/10.1126/science.abc6506 (2021).
Wang, Q., Holmes, W. R., Sosnik, J., Schilling, T. & Nie, Q. Cell sorting and noise-induced cell plasticity coordinate to sharpen boundaries between gene expression domains. PLoS Comput. Biol. 13, e1005307 (2017). Using computational modelling, this study proposes that boundary sharpening during developmental segmentation depends on adhesion-based and repulsion-based cell sorting, as well as noise-induced cell state transitions.
Wellens, T., Shatokhin, V. & Buchleitner, A. Stochastic resonance. Rep. Prog. Phys. 67, 45 (2003).
Matak, A. et al. Stochastic phenotype switching leads to intratumor heterogeneity in human liver cancer. Hepatology 68, 933–948 (2018).
Sosnik, J. et al. Noise modulation in retinoic acid signaling sharpens segmental boundaries of gene expression in the embryonic zebrafish hindbrain. eLife 5, e14034 (2016).
Zhang, L. et al. Noise drives sharpening of gene expression boundaries in the zebrafish hindbrain. Mol. Syst. Biol. 8, 613 (2012).
Chang, H. H., Hemberg, M., Barahona, M., Ingber, D. E. & Huang, S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 453, 544–547 (2008).
Eldar, A. & Elowitz, M. B. Functional roles for noise in genetic circuits. Nature 467, 167–173 (2010).
Pujadas, E. & Feinberg, A. P. Regulated noise in the epigenetic landscape of development and disease. Cell 148, 1123–1131 (2012).
Ozbudak, E. M., Thattai, M., Kurtser, I., Grossman, A. D. & van Oudenaarden, A. Regulation of noise in the expression of a single gene. Nat. Genet. 31, 69–73 (2002).
Battich, N., Stoeger, T. & Pelkmans, L. Control of transcript variability in single mammalian cells. Cell 163, 1596–1610 (2015).
Arias, A. M. & Hayward, P. Filtering transcriptional noise during development: concepts and mechanisms. Nat. Rev. Genet. 7, 34–44 (2006).
Bahar, R. et al. Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature 441, 1011–1014 (2006).
Kussell, E. & Leibler, S. Phenotypic diversity, population growth, and information in fluctuating environments. Science 309, 2075–2078 (2005).
Acar, M., Mettetal, J. T. & van Oudenaarden, A. Stochastic switching as a survival strategy in fluctuating environments. Nat. Genet. 40, 471–475 (2008).
Boulay, J. L., Dennefeld, C. & Alberga, A. The Drosophila developmental gene snail encodes a protein with nucleic acid binding fingers. Nature 330, 395–398 (1987).
Thisse, B., Stoetzel, C., Gorostiza-Thisse, C. & Perrin-Schmitt, F. Sequence of the twist gene and nuclear localization of its protein in endomesodermal cells of early Drosophila embryos. EMBO J. 7, 2175–2183 (1988).
Nieto, M. A., Bennett, M. F., Sargent, M. G. & Wilkinson, D. G. Cloning and developmental expression of Sna, a murine homologue of the Drosophila snail gene. Development 116, 227–237 (1992).
Funahashi, J., Sekido, R., Murai, K., Kamachi, Y. & Kondoh, H. δ-Crystallin enhancer binding protein δEF1 is a zinc finger-homeodomain protein implicated in postgastrulation embryogenesis. Development 119, 433–446 (1993).
Nieto, M. A., Sargent, M. G., Wilkinson, D. G. & Cooke, J. Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 264, 835–839 (1994).
Verschueren, K. et al. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5′-CACCT sequences in candidate target genes. J. Biol. Chem. 274, 20489–20498 (1999).
Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939 (2004).
Savagner, P., Yamada, K. M. & Thiery, J. P. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial–mesenchymal transition. J. Cell Biol. 137, 1403–1419 (1997).
Grooteclaes, M. L. & Frisch, S. M. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 19, 3823–3828 (2000).
Comijn, J. et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267–1278 (2001).
Cano, A. et al. The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76–83 (2000).
Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84–89 (2000).
Oba, S. et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS ONE 5, e13614 (2010).
Lovisa, S. et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21, 998–1009 (2015).
Kida, Y., Asahina, K., Teraoka, H., Gitelman, I. & Sato, T. Twist relates to tubular epithelial–mesenchymal transition and interstitial fibrogenesis in the obstructed kidney. J. Histochem. Cytochem. 55, 661–673 (2007).
Grande, M. T. et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21, 989–997 (2015). In this study, Snai1 reactivation in tubular epithelial cells is shown to induce a partial EMT, which indirectly promotes myofibroblast formation and fibrinogenesis.
Hajra, K. M., Chen, D. Y. & Fearon, E. R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62, 1613–1618 (2002).
Vesuna, F., van Diest, P., Chen, J. H. & Raman, V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys. Res. Commun. 367, 235–241 (2008).
Lehmann, W. et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498 (2016).
Mani, S. A. et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl Acad. Sci. USA 104, 10069–10074 (2007).
Hartwell, K. A. et al. The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc. Natl Acad. Sci. USA 103, 18969–18974 (2006).
Wang, X. et al. Kruppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 67, 7184–7193 (2007).
Takano, S. et al. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev. 30, 233–247 (2016).
Ocana, O. H. et al. Metastatic colonization requires the repression of the epithelial–mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012).
Tavares, A. L. P., Brown, J. A., Ulrich, E. C., Dvorak, K. & Runyan, R. B. Runx2-I is an early regulator of epithelial–mesenchymal cell transition in the chick embryo. Dev. Dyn. 247, 542–554 (2018).
McCoy, E. L. et al. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial–mesenchymal transition. J. Clin. Invest. 119, 2663–2677 (2009).
Perez-Moreno, M. A. et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial–mesenchymal transitions. J. Biol. Chem. 276, 27424–27431 (2001).
Sobrado, V. R. et al. The class I bHLH factors E2-2A and E2-2B regulate EMT. J. Cell Sci. 122, 1014–1024 (2009).
Stemmler, M. P., Eccles, R. L., Brabletz, S. & Brabletz, T. Non-redundant functions of EMT transcription factors. Nat. Cell Biol. 21, 102–112 (2019). This review discusses the specific, distinct functions of the core EMT-TFs.
Goossens, S., Vandamme, N., Van Vlierberghe, P. & Berx, G. EMT transcription factors in cancer development re-evaluated: beyond EMT and MET. Biochim. Biophys. Acta Rev. Cancer 1868, 584–591 (2017).
Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3, 155–166 (2002).
Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N. & Berx, G. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity. Trends Genet. 33, 943–959 (2017).
Kang, E., Seo, J., Yoon, H. & Cho, S. The post-translational regulation of epithelial–mesenchymal transition-inducing transcription factors in cancer metastasis. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22073591 (2021).
Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593–601 (2008).
Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894–907 (2008).
Kim, N. H. et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. J. Cell Biol. 195, 417–433 (2011).
Siemens, H. et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial–mesenchymal transitions. Cell Cycle 10, 4256–4271 (2011).
Lu, M., Jolly, M. K., Levine, H., Onuchic, J. N. & Ben-Jacob, E. microRNA-based regulation of epithelial–hybrid–mesenchymal fate determination. Proc. Natl Acad. Sci. USA 110, 18144–18149 (2013).
Zhang, J. et al. TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci. Signal. 7, ra91 (2014).
Tian, X. J., Zhang, H. & Xing, J. Coupled reversible and irreversible bistable switches underlying TGFβ-induced epithelial to mesenchymal transition. Biophys. J. 105, 1079–1089 (2013).
Liu, Y. et al. Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT. Nat. Commun. 10, 1637 (2019).
Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language. Cell 146, 353–358 (2011).
Gantier, M. P. et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 39, 5692–5703 (2011).
Bosson, A. D., Zamudio, J. R. & Sharp, P. A. Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition. Mol. Cell 56, 347–359 (2014).
Jansson, M. D. & Lund, A. H. microRNA and cancer. Mol. Oncol. 6, 590–610 (2012).
Cheng, J. T. et al. Insights into biological role of lncRNAs in epithelial–mesenchymal transition. Cells https://doi.org/10.3390/cells8101178 (2019).
O’Brien, S. J. et al. Long non-coding RNA (lncRNA) and epithelial–mesenchymal transition (EMT) in colorectal cancer: a systematic review. Cancer Biol. Ther. 21, 769–781 (2020).
Zhang, J. et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteom. Bioinforma. 13, 17–24 (2015).
Dragomir, M., Chen, B. & Calin, G. A. Exosomal lncRNAs as new players in cell-to-cell communication. Transl. Cancer Res. 7, S243–S252 (2018).
Zhang, X. et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol. Cancer 18, 40 (2019).
Li, Z. et al. Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma. Oncogene 37, 3822–3838 (2018).
Wang, X. et al. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Cell Death Dis. 9, 940 (2018).
Pan, L. et al. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J. Cancer Res. Clin. Oncol. 143, 991–1004 (2017).
Wu, D. M. et al. TGF-β-mediated exosomal lnc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression. Cancer Med. 7, 5118–5129 (2018).
Xue, M. et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol. Cancer 16, 143 (2017).
Javaid, S. et al. Dynamic chromatin modification sustains epithelial–mesenchymal transition following inducible expression of Snail-1. Cell Rep. 5, 1679–1689 (2013).
Graff, J. R., Gabrielson, E., Fujii, H., Baylin, S. B. & Herman, J. G. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 275, 2727–2732 (2000).
Cheng, C. W. et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20, 3814–3823 (2001).
Lombaerts, M. et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 94, 661–671 (2006).
Chen, Y., Wang, K., Qian, C. N. & Leach, R. DNA methylation is associated with transcription of Snail and Slug genes. Biochem. Biophys. Res. Commun. 430, 1083–1090 (2013).
Galvan, J. A. et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial–mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 6, 874–885 (2015).
Alghamian, Y., Soukkarieh, C., Abbady, A. Q. & Murad, H. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line. Sci. Rep. 12, 7494 (2022).
Vrba, L. et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 5, e8697 (2010).
Wiklund, E. D. et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 128, 1327–1334 (2011).
Davalos, V. et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31, 2062–2074 (2012).
Tellez, C. S. et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 71, 3087–3097 (2011).
Dang, T. T., Esparza, M. A., Maine, E. A., Westcott, J. M. & Pearson, G. W. DeltaNp63α promotes breast cancer cell motility through the selective activation of components of the epithelial-to-mesenchymal transition program. Cancer Res. 75, 3925–3935 (2015).
Abell, A. N. et al. MAP3K4/CBP-regulated H2B acetylation controls epithelial–mesenchymal transition in trophoblast stem cells. Cell Stem Cell 8, 525–537 (2011).
Warzecha, C. C., Sato, T. K., Nabet, B., Hogenesch, J. B. & Carstens, R. P. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell 33, 591–601 (2009).
Segelle, A. et al. Histone marks regulate the epithelial-to-mesenchymal transition via alternative splicing. Cell Rep. 38, 110357 (2022). This study illustrates how histone modifications can interact with splicing regulators, consequently driving alternative splicing programmes that underlie EMTs.
Sahu, S. K. et al. A complex epigenome-splicing crosstalk governs epithelial-to-mesenchymal transition in metastasis and brain development. Nat. Cell Biol. 24, 1265–1277 (2022).
Gomes, A. P. et al. Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization. Cancer Cell 36, 402–417.e13 (2019).
Hodge, D. Q., Cui, J., Gamble, M. J. & Guo, W. Histone variant macroH2A1 plays an isoform-specific role in suppressing epithelial–mesenchymal transition. Sci. Rep. 8, 841 (2018).
Dumont, N. et al. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl Acad. Sci. USA 105, 14867–14872 (2008).
Galle, E. et al. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin. Epigenetics 12, 27 (2020).
Jia, W., Deshmukh, A., Mani, S. A., Jolly, M. K. & Levine, H. A possible role for epigenetic feedback regulation in the dynamics of the epithelial–mesenchymal transition (EMT). Phys. Biol. 16, 066004 (2019).
Yuan, S. et al. Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression. Cancer Discov. 10, 854–871 (2020).
Morin, C., Moyret-Lalle, C., Mertani, H. C., Diaz, J. J. & Marcel, V. Heterogeneity and dynamic of EMT through the plasticity of ribosome and mRNA translation. Biochim. Biophys. Acta Rev. Cancer 1877, 188718 (2022).
Willig, T. N. et al. Mutations in ribosomal protein S19 gene and Diamond Blackfan anemia: wide variations in phenotypic expression. Blood 94, 4294–4306 (1999).
Boria, I. et al. The ribosomal basis of Diamond–Blackfan anemia: mutation and database update. Hum. Mutat. 31, 1269–1279 (2010).
Lipton, J. M. & Ellis, S. R. Diamond–Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol. Oncol. Clin. North. Am. 23, 261–282 (2009).
Dauwerse, J. G. et al. Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome. Nat. Genet. 43, 20–22 (2011).
Valdez, B. C., Henning, D., So, R. B., Dixon, J. & Dixon, M. J. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor. Proc. Natl Acad. Sci. USA 101, 10709–10714 (2004).
Wielosz, E., Dryglewska, M. & Majdan, M. Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis. Postepy Dermatol. Alergol. 37, 909–914 (2020).
Ochs, R. L., Lischwe, M. A., Spohn, W. H. & Busch, H. Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol. Cell 54, 123–133 (1985).
Arnett, F. C. et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 39, 1151–1160 (1996).
Bassler, J. & Hurt, E. Eukaryotic ribosome assembly. Annu. Rev. Biochem. 88, 281–306 (2019).
Benyelles, M. et al. NHP2 deficiency impairs rRNA biogenesis and causes pulmonary fibrosis and Hoyeraal–Hreidarsson syndrome. Hum. Mol. Genet. 29, 907–922 (2020).
Freed, E. F. & Baserga, S. J. The C-terminus of Utp4, mutated in childhood cirrhosis, is essential for ribosome biogenesis. Nucleic Acids Res. 38, 4798–4806 (2010).
Freed, E. F., Prieto, J. L., McCann, K. L., McStay, B. & Baserga, S. J. NOL11, implicated in the pathogenesis of North American Indian childhood cirrhosis, is required for pre-rRNA transcription and processing. PLoS Genet. 8, e1002892 (2012).
Thorolfsdottir, R. B. et al. Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Commun. Biol. 1, 68 (2018).
Prakash, V. et al. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nat. Commun. 10, 2110 (2019).
Hou, Y. et al. Airway basal cells mediate hypoxia-induced EMT by increasing ribosome biogenesis. Front. Pharmacol. 12, 783946 (2021).
Ito, N. et al. Ribosome incorporation into somatic cells promotes lineage transdifferentiation towards multipotency. Sci. Rep. 8, 1634 (2018).
Kudo, M. et al. Ribosome incorporation induces EMT-like phenomenon with cell cycle arrest in human breast cancer cell. Cell Tissues Organs 211, 212–221 (2022).
Mili, S., Moissoglu, K. & Macara, I. G. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions. Nature 453, 115–119 (2008).
Mardakheh, F. K. et al. Global analysis of mRNA, translation, and protein localization: local translation is a key regulator of cell protrusions. Dev. Cell 35, 344–357 (2015).
Wang, X. et al. Methyltransferase like 13 mediates the translation of Snail in head and neck squamous cell carcinoma. Int. J. Oral. Sci. 13, 26 (2021).
Dermit, M. et al. Subcellular mRNA localization regulates ribosome biogenesis in migrating cells. Dev. Cell 55, 298–313 e210 (2020). This article reveals how cellular protrusions formed during EMT act as hot spots for RP-coding RNA translation, enhancing ribosome biogenesis and overall protein synthesis in migratory cells.
Lin, X. et al. RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nat. Commun. 10, 2065 (2019).
Chaudhury, A. et al. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat. Commun. 7, 13362 (2016).
Evdokimova, V. et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial–mesenchymal transition. Cancer Cell 15, 402–415 (2009).
Gulhati, P. et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 71, 3246–3256 (2011).
Cai, W., Ye, Q. & She, Q. B. Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. Oncotarget 5, 6015–6027 (2014).
Azmi, A. S. et al. Targeting the nuclear export protein XPO1/CRM1 reverses epithelial to mesenchymal transition. Sci. Rep. 5, 16077 (2015).
Kang, H., Kim, H., Lee, S., Youn, H. & Youn, B. Role of metabolic reprogramming in epithelial–mesenchymal transition (EMT). Int. J. Mol. Sci. https://doi.org/10.3390/ijms20082042 (2019).
Georgakopoulos-Soares, I., Chartoumpekis, D. V., Kyriazopoulou, V. & Zaravinos, A. EMT factors and metabolic pathways in cancer. Front. Oncol. 10, 499 (2020).
Sciacovelli, M. & Frezza, C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 284, 3132–3144 (2017).
Hua, W., Ten Dijke, P., Kostidis, S., Giera, M. & Hornsveld, M. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol. Life Sci. 77, 2103–2123 (2020).
Cha, Y. H., Yook, J. I., Kim, H. S. & Kim, N. H. Catabolic metabolism during cancer EMT. Arch. Pharm. Res. 38, 313–320 (2015).
Swinnen, J. V., Brusselmans, K. & Verhoeven, G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9, 358–365 (2006).
Kuhajda, F. P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66, 5977–5980 (2006).
Zhu, Y. et al. Posttranslational control of lipogenesis in the tumor microenvironment. J. Hematol. Oncol. 15, 120 (2022).
Singh, R., Yadav, V., Kumar, S. & Saini, N. microRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci. Rep. 5, 17454 (2015).
Gong, J. et al. Inhibition of FASN suppresses migration, invasion and growth in hepatoma carcinoma cells by deregulating the HIF-1α/IGFBP1 pathway. Int. J. Oncol. 50, 883–892 (2017).
Jiang, L. et al. Up-regulated FASN expression promotes transcoelomic metastasis of ovarian cancer cell through epithelial–mesenchymal transition. Int. J. Mol. Sci. 15, 11539–11554 (2014).
Sun, L. et al. Small interfering RNA-mediated knockdown of fatty acid synthase attenuates the proliferation and metastasis of human gastric cancer cells via the mTOR/Gli1 signaling pathway. Oncol. Lett. 16, 594–602 (2018).
Yang, L. et al. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer. Oncotarget 7, 55543–55554 (2016).
Gonzalez-Guerrico, A. M. et al. Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. Oncotarget 7, 71151–71168 (2016).
Chen, Y. et al. ZEB1 regulates multiple oncogenic components involved in uveal melanoma progression. Sci. Rep. 7, 45 (2017).
Hung, C. M. et al. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial–mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J. Agric. Food Chem. 59, 9683–9690 (2011).
Angelucci, C. et al. Epithelial–stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness. PLoS ONE 7, e50804 (2012).
Edmond, V. et al. Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. Oncogene 34, 996–1005 (2015).
Taraboletti, G. et al. Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. Int. J. Cancer 44, 707–713 (1989).
Zhao, W. et al. Candidate antimetastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity. Cancer Res. 76, 2037–2049 (2016).
Wang, Y. et al. NNMT contributes to high metastasis of triple negative breast cancer by enhancing PP2A/MEK/ERK/c-Jun/ABCA1 pathway mediated membrane fluidity. Cancer Lett. 547, 215884 (2022).
Eiriksson, F. F. et al. Altered plasmalogen content and fatty acid saturation following epithelial to mesenchymal transition in breast epithelial cell lines. Int. J. Biochem. Cell Biol. 103, 99–104 (2018).
Yu, H., Duan, P., Zhu, H. & Rao, D. miR-613 inhibits bladder cancer proliferation and migration through targeting SphK1. Am. J. Transl. Res. 9, 1213–1221 (2017).
Fan, Z., Jiang, H., Wang, Z. & Qu, J. Atorvastatin partially inhibits the epithelial–mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1. Oncol. Rep. 36, 1016–1022 (2016).
Long, J., Xie, Y., Yin, J., Lu, W. & Fang, S. SphK1 promotes tumor cell migration and invasion in colorectal cancer. Tumour Biol. 37, 6831–6836 (2016).
Liu, H., Ma, Y., He, H. W., Zhao, W. L. & Shao, R. G. SPHK1 (sphingosine kinase 1) induces epithelial–mesenchymal transition by promoting the autophagy-linked lysosomal degradation of CDH1/E-cadherin in hepatoma cells. Autophagy 13, 900–913 (2017).
Xu, C. Y. et al. SphK1 modulates cell migration and EMT-related marker expression by regulating the expression of p-FAK in colorectal cancer cells. Int. J. Mol. Med. 39, 1277–1284 (2017).
Meshcheryakova, A. et al. Exploring the role of sphingolipid machinery during the epithelial to mesenchymal transition program using an integrative approach. Oncotarget 7, 22295–22323 (2016).
Zeng, Y. et al. Sphingosine-1-phosphate induced epithelial–mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-β autocrine loop. Oncotarget 7, 63324–63337 (2016).
Ishizawa, S. et al. Sphingosine-1-phosphate induces differentiation of cultured renal tubular epithelial cells under Rho kinase activation via the S1P2 receptor. Clin. Exp. Nephrol. 18, 844–852 (2014).
Zeng, Y. E., Yao, X. H., Yan, Z. P., Liu, J. X. & Liu, X. H. Potential signaling pathway involved in sphingosine-1-phosphate-induced epithelial–mesenchymal transition in cancer. Oncol. Lett. 12, 379–382 (2016).
Fajardo, V. A., McMeekin, L. & LeBlanc, P. J. Influence of phospholipid species on membrane fluidity: a meta-analysis for a novel phospholipid fluidity index. J. Membr. Biol. 244, 97–103 (2011).
Ruiz, M. et al. Sphingosine 1-phosphate mediates adiponectin receptor signaling essential for lipid homeostasis and embryogenesis. Nat. Commun. 13, 7162 (2022).
Lu, P., White-Gilbertson, S., Nganga, R., Kester, M. & Voelkel-Johnson, C. Expression of the SNAI2 transcriptional repressor is regulated by C16-ceramide. Cancer Biol. Ther. 20, 922–930 (2019).
Prijic, S. & Chang, J. T. ABCA1 expression is upregulated in an EMT in breast cancer cell lines via MYC-mediated de-repression of its proximal ebox element. Biomedicines https://doi.org/10.3390/biomedicines10030581 (2022).
Alonso, A. & Goni, F. M. The physical properties of ceramides in membranes. Annu. Rev. Biophys. 47, 633–654 (2018).
van Blitterswijk, W. J., van der Meer, B. W. & Hilkmann, H. Quantitative contributions of cholesterol and the individual classes of phospholipids and their degree of fatty acyl (un)saturation to membrane fluidity measured by fluorescence polarization. Biochemistry 26, 1746–1756 (1987).
Dalmau, N., Jaumot, J., Tauler, R. & Bedia, C. Epithelial-to-mesenchymal transition involves triacylglycerol accumulation in DU145 prostate cancer cells. Mol. Biosyst. 11, 3397–3406 (2015).
Lin, S. J., Yang, D. R., Li, G. & Chang, C. TR4 nuclear receptor different roles in prostate cancer progression. Front. Endocrinol. 6, 78 (2015).
Xu, X. et al. VSP-17 suppresses the migration and invasion of triple-negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway. Oncol. Rep. 45, 975–986 (2021).
Reka, A. K. et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial–mesenchymal transition. Mol. Cancer Ther. 9, 3221–3232 (2010).
Liu, J. et al. Bergenin inhibits bladder cancer progression via activating the PPARγ/PTEN/Akt signal pathway. Drug Dev. Res. 82, 278–286 (2021).
Di Gregorio, J. et al. Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. PLoS ONE 12, e0171093 (2017).
Wu, C. T., Wang, C. C., Huang, L. C., Liu, S. H. & Chiang, C. K. Plasticizer di-(2-ethylhexyl)phthalate induces epithelial-to-mesenchymal transition and renal fibrosis in vitro and in vivo. Toxicol. Sci. 164, 363–374 (2018).
Wang, Q. et al. Integrin β4 in EMT: an implication of renal diseases. Int. J. Clin. Exp. Med. 8, 6967–6976 (2015).
Bai, X., Hou, X., Tian, J., Geng, J. & Li, X. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARγ pathway. Oncotarget 7, 36510–36528 (2016).
Li, R. et al. Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not Smad pathway in renal tubular epithelial cells. PLoS ONE 8, e58848 (2013).
Bocca, C. et al. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert. Opin. Ther. Targets 18, 121–135 (2014).
Li, Z. L. et al. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology 4, e1044712 (2015).
Che, D. et al. Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/β-catenin signalling pathway. Mol. Immunol. 90, 197–210 (2017).
Qin, G. et al. Palbociclib inhibits epithelial–mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget 6, 41794–41808 (2015).
Wang, Y. P., Wang, Q. Y., Li, C. H. & Li, X. W. COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. Chem. Biol. Interact. 292, 24–29 (2018).
Xu, Z. et al. Lipoxin A4 interferes with embryo implantation via suppression of epithelial–mesenchymal transition. Am. J. Reprod. Immunol. 81, e13107 (2019).
Wu, R. F. et al. Lipoxin A4 suppresses estrogen-induced epithelial–mesenchymal transition via ALXR-dependent manner in endometriosis. Reprod. Sci. 25, 566–578 (2018).
Yang, J. X. et al. Lipoxin A4 ameliorates lipopolysaccharide-induced lung injury through stimulating epithelial proliferation, reducing epithelial cell apoptosis and inhibits epithelial–mesenchymal transition. Respir. Res. 20, 192 (2019).
Rodgers, K., McMahon, B., Mitchell, D., Sadlier, D. & Godson, C. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am. J. Pathol. 167, 683–694 (2005).
Xu, F. et al. Lipoxin A4 and its analog suppress hepatocarcinoma cell epithelial–mesenchymal transition, migration and metastasis via regulating integrin-linked kinase axis. Prostaglandins Other Lipid Mediat. 137, 9–19 (2018).
Zong, L. et al. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. J. Exp. Clin. Cancer Res. 36, 181 (2017).
Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).
Hamabe, A. et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial–mesenchymal transition. Proc. Natl Acad. Sci. USA 111, 15526–15531 (2014).
Fan, F. T. et al. PKM2 regulates hepatocellular carcinoma cell epithelial–mesenchymal transition and migration upon EGFR activation. Asian Pac. J. Cancer Prev. 15, 1961–1970 (2014).
Chen, G. et al. Deregulation of hexokinase II is associated with glycolysis, autophagy, and the epithelial–mesenchymal transition in tongue squamous cell carcinoma under hypoxia. Biomed. Res. Int. 2018, 8480762 (2018).
Wang, Y. et al. LncRNA-p23154 promotes the invasion-metastasis potential of oral squamous cell carcinoma by regulating Glut1-mediated glycolysis. Cancer Lett. 434, 172–183 (2018).
Yalcin, A. et al. 6-Phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is required for transforming growth factor β1-enhanced invasion of Panc1 cells in vitro. Biochem. Biophys. Res. Commun. 484, 687–693 (2017).
Lunetti, P. et al. Metabolic reprogramming in breast cancer results in distinct mitochondrial bioenergetics between luminal and basal subtypes. FEBS J. 286, 688–709 (2019).
Zhang, J. et al. TGF-β1 induces epithelial-to-mesenchymal transition via inhibiting mitochondrial functions in A549 cells. Free Radic. Res. 52, 1432–1444 (2018).
Yi, E. Y., Park, S. Y., Jung, S. Y., Jang, W. J. & Kim, Y. J. Mitochondrial dysfunction induces EMT through the TGF-β/Smad/Snail signaling pathway in Hep3B hepatocellular carcinoma cells. Int. J. Oncol. 47, 1845–1853 (2015).
Guha, M. et al. Mitochondrial retrograde signaling induces epithelial–mesenchymal transition and generates breast cancer stem cells. Oncogene 33, 5238–5250 (2014).
Li, X. et al. Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16INK4a inactivation. J. Exp. Clin. Cancer Res. 37, 39 (2018).
Fiaschi, T. et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor–stroma interplay. Cancer Res. 72, 5130–5140 (2012).
Wang, H. et al. TOP1MT deficiency promotes GC invasion and migration via the enhancements of LDHA expression and aerobic glycolysis. Endocr. Relat. Cancer 24, 565–578 (2017).
Park, G. B. & Kim, D. TLR4-mediated galectin-1 production triggers epithelial–mesenchymal transition in colon cancer cells through ADAM10- and ADAM17-associated lactate production. Mol. Cell Biochem. 425, 191–202 (2017).
Corbet, C. et al. TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat. Commun. 11, 454 (2020).
Bhattacharya, D., Azambuja, A. P. & Simoes-Costa, M. Metabolic reprogramming promotes neural crest migration via Yap/Tead signaling. Dev. Cell 53, 199–211.e6 (2020).
Bulusu, V. et al. Spatiotemporal analysis of a glycolytic activity gradient linked to mouse embryo mesoderm development. Dev. Cell 40, 331–341.e4 (2017).
Oginuma, M. et al. A gradient of glycolytic activity coordinates FGF and Wnt signaling during elongation of the body axis in amniote embryos. Dev. Cell 40, 342–353.e10 (2017).
Youssef, K. K. & Nieto, M. A. Glucose metabolism takes center stage in epithelial–mesenchymal plasticity. Dev. Cell 53, 133–135 (2020).
Rossi, M. et al. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. Nature 605, 747–753 (2022).
Schwager, S. C. et al. Link between glucose metabolism and epithelial-to-mesenchymal transition drives triple-negative breast cancer migratory heterogeneity. iScience 25, 105190 (2022). This report links migratory ability and EMT status to glucose metabolism in triple-negative breast cancer cells.
Siddiqui, A. et al. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. Cell Death Differ. 26, 2223–2236 (2019).
Ramesh, V., Brabletz, T. & Ceppi, P. Targeting EMT in cancer with repurposed metabolic inhibitors. Trends Cancer 6, 942–950 (2020).
Luond, F. et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev. Cell 56, 3203–3221 e3211 (2021). Using tracing systems, this study finds that partial, but not full, EMT contributes to metastasis, whereas full EMT contributes to chemoresistance.
Verstappe, J. & Berx, G. A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer. Semin. Cancer Biol. 90, 15–28 (2023).
Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325–338 (2021).
Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).
Schliekelman, M. J. et al. Molecular portraits of epithelial, mesenchymal, and hybrid states in lung adenocarcinoma and their relevance to survival. Cancer Res. 75, 1789–1800 (2015).
Ruscetti, M., Quach, B., Dadashian, E. L., Mulholland, D. J. & Wu, H. Tracking and functional characterization of epithelial–mesenchymal transition and mesenchymal tumor cells during prostate cancer metastasis. Cancer Res. 75, 2749–2759 (2015).
Cook, D. P. & Wrana, J. L. A specialist-generalist framework for epithelial–mesenchymal plasticity in cancer. Trends Cancer 8, 358–368 (2022).
Saxena, K., Jolly, M. K. & Balamurugan, K. Hypoxia, partial EMT and collective migration: emerging culprits in metastasis. Transl. Oncol. 13, 100845 (2020).
Quan, Q. et al. Cancer stem-like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion. Cancer Sci. 111, 467–476 (2020).
Jia, D. et al. OVOL guides the epithelial–hybrid–mesenchymal transition. Oncotarget 6, 15436–15448 (2015).
Jolly, M. K. et al. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 7, 27067–27084 (2016).
Bocci, F. et al. Numb prevents a complete epithelial–mesenchymal transition by modulating Notch signalling. J. R. Soc. Interface https://doi.org/10.1098/rsif.2017.0512 (2017).
Subbalakshmi, A. R. et al. NFATc acts as a non-canonical phenotypic stability factor for a hybrid epithelial/mesenchymal phenotype. Front. Oncol. 10, 553342 (2020).
Vilchez Mercedes, S. A. et al. Nrf2 modulates the hybrid epithelial/mesenchymal phenotype and notch signaling during collective cancer migration. Front. Mol. Biosci. 9, 807324 (2022).
Bocci, F. et al. NRF2 activates a partial epithelial–mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype. Integr. Biol. 11, 251–263 (2019).
Chung, V. Y. et al. GRHL2–miR-200–ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Sci. Rep. 6, 19943 (2016).
Jolly, M. K. et al. Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer 3, 21 (2017).
Subbalakshmi, A. R., Sahoo, S., Biswas, K. & Jolly, M. K. A computational systems biology approach identifies SLUG as a mediator of partial epithelial–mesenchymal transition (EMT). Cells Tissues Organs 211, 689–702 (2021).
Biswas, K., Jolly, M. K. & Ghosh, A. Stability and mean residence times for hybrid epithelial/mesenchymal phenotype. Phys. Biol. 16, 025003 (2019).
Zander, M. A., Cancino, G. I., Gridley, T., Kaplan, D. R. & Miller, F. D. The Snail transcription factor regulates the numbers of neural precursor cells and newborn neurons throughout mammalian life. PLoS ONE 9, e104767 (2014).
Wang, H. et al. ZEB1 represses neural differentiation and cooperates with CTBP2 to dynamically regulate cell migration during neocortex development. Cell Rep. 27, 2335–2353.e6 (2019).
Deryckere, A. et al. Multifaceted actions of Zeb2 in postnatal neurogenesis from the ventricular–subventricular zone to the olfactory bulb. Development https://doi.org/10.1242/dev.184861 (2020).
Di Filippo, E. S. et al. Zeb2 Regulates myogenic differentiation in pluripotent stem cells. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21072525 (2020).
Choi, I. Y. et al. Transcriptional landscape of myogenesis from human pluripotent stem cells reveals a key role of TWIST1 in maintenance of skeletal muscle progenitors. eLife https://doi.org/10.7554/eLife.46981 (2020).
Gubelmann, C. et al. Identification of the transcription factor ZEB1 as a central component of the adipogenic gene regulatory network. eLife 3, e03346 (2014).
Goossens, S. et al. The EMT regulator Zeb2/Sip1 is essential for murine embryonic hematopoietic stem/progenitor cell differentiation and mobilization. Blood 117, 5620–5630 (2011).
Scott, C. L. & Omilusik, K. D. ZEBs: novel players in immune cell development and function. Trends Immunol. 40, 431–446 (2019).
Wang, J. et al. Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity. PLoS Biol. 19, e3001394 (2021).
Denecker, G. et al. Identification of a ZEB2–MITF–ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ. 21, 1250–1261 (2014).
Bruneel, K., Verstappe, J., Vandamme, N. & Berx, G. Intrinsic balance between ZEB family members is important for melanocyte homeostasis and melanoma progression. Cancers https://doi.org/10.3390/cancers12082248 (2020).
Vandamme, N. & Berx, G. Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity. Front. Oncol. 4, 352 (2014).
Goossens, S. et al. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat. Commun. 6, 5794 (2015).
Tang, Y., Durand, S., Dalle, S. & Caramel, J. EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment. Cancers https://doi.org/10.3390/cancers12082154 (2020).
Pedri, D., Karras, P., Landeloos, E., Marine, J. C. & Rambow, F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 289, 1352–1368 (2022).
Soen, B. et al. ZEB proteins in leukemia: friends, foes, or friendly foes. Hemasphere 2, e43 (2018).
Goossens, S. et al. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms. Haematologica 104, 1608–1616 (2019).
Vandamme, N. et al. The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype. Cancer Res. 80, 2983–2995 (2020).
Ishay-Ronen, D. et al. Gain fat-lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell 35, 17–32 e16 (2019). This report displays how the plasticity of cancer cells undergoing EMT can be exploited therapeutically: by forcing transdifferentiation of EMP-displaying breast cancer cells towards the adipocyte lineage, invasion and metastasis are significantly repressed.
Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
Jolly, M. K., Ware, K. E., Gilja, S., Somarelli, J. A. & Levine, H. EMT and MET: necessary or permissive for metastasis? Mol. Oncol. 11, 755–769 (2017).
Suter, D. M. et al. Mammalian genes are transcribed with widely different bursting kinetics. Science 332, 472–474 (2011).
Urban, E. A. & Johnston, R. J. Jr. Buffering and amplifying transcriptional noise during cell fate specification. Front. Genet. 9, 591 (2018).
Becskei, A. & Serrano, L. Engineering stability in gene networks by autoregulation. Nature 405, 590–593 (2000).
Stoeger, T., Battich, N. & Pelkmans, L. Passive noise filtering by cellular compartmentalization. Cell 164, 1151–1161 (2016).
Klosin, A. et al. Phase separation provides a mechanism to reduce noise in cells. Science 367, 464–468 (2020).
Saunders, T. E. et al. Noise reduction in the intracellular pom1p gradient by a dynamic clustering mechanism. Dev. Cell 22, 558–572 (2012).
Brennan, C. M. et al. Protein aggregation mediates stoichiometry of protein complexes in aneuploid cells. Genes Dev. 33, 1031–1047 (2019).
Acknowledgements
J.H. is supported by a personal PhD fellowship from FWO (11H9523N). G.B.’s laboratory is supported by the Geconcerteerde Onderzoeksacties Ghent University (BOF.GOA.2021.0005.02), Kom Op Tegen Kanker (STI.DIV.2020.0017.01) and Stichting tegen Kanker (STI.STK.2021.0001.01).
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Genetics thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Haerinck, J., Goossens, S. & Berx, G. The epithelial–mesenchymal plasticity landscape: principles of design and mechanisms of regulation. Nat Rev Genet 24, 590–609 (2023). https://doi.org/10.1038/s41576-023-00601-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41576-023-00601-0
This article is cited by
-
Complex and variable regulation of ΔNp63 and TAp63 by TGFβ has implications for the dynamics of squamous cell epithelial to mesenchymal transition
Scientific Reports (2024)
-
Circulating tumor cell-derived preclinical models: current status and future perspectives
Cell Death & Disease (2023)
-
Inflammatory macrophages reprogram to immunosuppression by reducing mitochondrial translation
Nature Communications (2023)
-
Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination
Nature Communications (2023)
